TY - JOUR
T1 - Ambulatory function and mortality among cancer survivors in the NIH-AARP diet and health study
AU - Salerno, Elizabeth A.
AU - Saint-Maurice, Pedro F.
AU - Willis, Erik A.
AU - Moore, Steven C.
AU - DiPietro, Loretta
AU - Matthews, Charles E.
N1 - Funding Information:
This research was supported (in part) by the Intramural Research Program of the NIH, NCI. Cancer incidence data from the Atlanta metropolitan area were collected by the Georgia Center for Cancer Statistics, Department of Epidemiology, Rollins School of Public Health, Emory University (Atlanta, GA). Cancer incidence data from California were collected by the California Cancer Registry, California Department of Public Health's Cancer Surveillance and Research Branch (Sacramento, CA). Cancer incidence data from the Detroit metropolitan area were collected by the Michigan Cancer Surveillance Program,Community Health Administration (Lansing, MI). The Florida cancer incidence data used in this report were collected by the Florida Cancer Data System (Miami, FL) under contract with the Florida Department of Health (Tallahassee, FL). Cancer incidence data from Louisiana were collected by the Louisiana Tumor Registry, Louisiana State University Health Sciences Center School of Public Health (New Orleans, LA). Cancer incidence data from New Jersey were collected by the New Jersey State Cancer Registry, The Rutgers Cancer Institute of New Jersey (New Brunswick, NJ). Cancer incidence data from North Carolina were collected by the North Carolina Central Cancer Registry (Raleigh, NC). Cancer incidence data from Pennsylvania were supplied by the Division of Health Statistics and Research, Pennsylvania Department of Health (Harrisburg, PA). Cancer incidence data from Arizona were collected by the Arizona Cancer Registry, Division of Public Health Services, ArizonaDepartment ofHealth Services (Phoenix, AZ).Cancer incidence data from Texas were collected by the Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services (Austin, TX). Cancer incidence data from Nevada were collected by the Nevada Central Cancer Registry, Division of Public and Behavioral Health, State of Nevada Department ofHealth and Human Services (Carson City,NV).Weare indebted to the participants in the NIH-AARP Diet and Health Study for their outstanding cooperation. We also thank Sigurd Hermansen and Kerry Grace Morrissey from Westat for study outcomes ascertainment and management and Leslie Carroll at Information Management Services for data support and analysis.
Funding Information:
This research was supported (in part) by the Intramural Research Program of the NIH, NCI. Cancer incidence data from the Atlanta metropolitan area were collected by the Georgia Center for Cancer Statistics, Department of Epidemiology, Rollins School of Public Health, Emory University (Atlanta, GA). Cancer incidence data from California were collected by the California Cancer Registry, California Department of Public Health’s Cancer Surveillance and Research Branch (Sacramento, CA). Cancer incidence data from the Detroit metropolitan area were collected by the Michigan Cancer Surveillance Program, Community Health Administration (Lansing, MI). The Florida cancer incidence data used in this report were collected by the Florida Cancer Data System (Miami, FL) under contract with the Florida Department of Health (Tallahassee, FL). Cancer incidence data from Louisiana were collected by the Louisiana Tumor Registry, Louisiana State University Health Sciences Center School of Public Health (New Orleans, LA). Cancer incidence data from New Jersey were collected by the New Jersey State Cancer Registry, The Rutgers Cancer Institute of New Jersey (New Brunswick, NJ). Cancer incidence data from North Carolina were collected by the North Carolina Central Cancer Registry (Raleigh, NC). Cancer incidence data from Pennsylvania were supplied by the Division of Health Statistics and Research, Pennsylvania Department of Health (Harrisburg, PA). Cancer inci-
Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/4
Y1 - 2021/4
N2 - Background: There is limited evidence describing associations between cancer and function in diverse cancer types and its relationship with mortality. We investigated the relationship between cancer and poor ambulatory function and associations between ambulatory function and subsequent mortality. Methods: Participants included 233,135 adults (n = 30,403 cancer and n = 202,732 cancer free) in the NIH-American Association of Retired Persons Diet and Health Study (1994- 1996) who self-reported ambulatory function (e.g., walking pace and mobility disability: being unable to walk or walking at the slowest pace) in 2004-2006. Participants were followed for mortality from the assessment of ambulatory function through 2011. Multinomial logistic regression quantified the association between cancer and ambulatory function. We then explored the independent effects of walking pace and mobility disability in cancer survivors, and the joint effects of both a cancer diagnosis and poor ambulatory function on mortality using Cox proportional hazards models. Models explored type-specific associations across 15 cancer types. Results: Survivors had 42% greater odds of walking at the slowest pace [OR, 1.42 (confidence interval (CI), 1.30-1.54)] and 24% greater odds of mobility disability [OR, 1.24 (CI, 1.17-1.31)], compared with cancer-free participants, adjusting for baseline demographics, health indicators, and cancer type. Survivors reporting the slowest pace were at increased hazards than those who walked the fastest: all-cause mortality [HR, 2.22 (CI, 2.06-2.39)] and cancer mortality [HR, 2.12 (CI, 1.83-2.45)]. Similar trends emerged for mobility disability (HRs > 1.64). All-cause mortality associations were significant for more than nine cancer types. Conclusions: A diagnosis of cancer is associated with poorer ambulatory function, which is subsequently associated with increased mortality. Impact: Widespread efforts should target ambulatory function during cancer survivorship for survival benefits.
AB - Background: There is limited evidence describing associations between cancer and function in diverse cancer types and its relationship with mortality. We investigated the relationship between cancer and poor ambulatory function and associations between ambulatory function and subsequent mortality. Methods: Participants included 233,135 adults (n = 30,403 cancer and n = 202,732 cancer free) in the NIH-American Association of Retired Persons Diet and Health Study (1994- 1996) who self-reported ambulatory function (e.g., walking pace and mobility disability: being unable to walk or walking at the slowest pace) in 2004-2006. Participants were followed for mortality from the assessment of ambulatory function through 2011. Multinomial logistic regression quantified the association between cancer and ambulatory function. We then explored the independent effects of walking pace and mobility disability in cancer survivors, and the joint effects of both a cancer diagnosis and poor ambulatory function on mortality using Cox proportional hazards models. Models explored type-specific associations across 15 cancer types. Results: Survivors had 42% greater odds of walking at the slowest pace [OR, 1.42 (confidence interval (CI), 1.30-1.54)] and 24% greater odds of mobility disability [OR, 1.24 (CI, 1.17-1.31)], compared with cancer-free participants, adjusting for baseline demographics, health indicators, and cancer type. Survivors reporting the slowest pace were at increased hazards than those who walked the fastest: all-cause mortality [HR, 2.22 (CI, 2.06-2.39)] and cancer mortality [HR, 2.12 (CI, 1.83-2.45)]. Similar trends emerged for mobility disability (HRs > 1.64). All-cause mortality associations were significant for more than nine cancer types. Conclusions: A diagnosis of cancer is associated with poorer ambulatory function, which is subsequently associated with increased mortality. Impact: Widespread efforts should target ambulatory function during cancer survivorship for survival benefits.
UR - http://www.scopus.com/inward/record.url?scp=85103862796&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-20-1473
DO - 10.1158/1055-9965.EPI-20-1473
M3 - Article
C2 - 33664017
AN - SCOPUS:85103862796
SN - 1055-9965
VL - 30
SP - 690
EP - 698
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 4
ER -